SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Microcap & Penny Stocks : NEOTHERAPEUTICS (NEOT) (NEOTW) -- Ignore unavailable to you. Want to Upgrade?


To: Orwell who wrote (631)1/29/1999 1:36:00 PM
From: Marty  Respond to of 705
 
Orwell, you have the right reasons to be interested in the company. Their drug works and the market for it is huge. I've been following developments for a long time now and followed every test. Each one has produced results better than expected. It originally amazed me, when I first heard about it, that they could show memory improvement in laboratory animals. Now, they have demonstrated the same results in humans, besides overcoming all the other issues. It still takes more time to do more testing with bigger groups to confirm results. Still, it is so far, so good.

You can get a much better idea of what is involved and how the drug works from their web site at neotherapeutics.com. There are some animations of the process and posts of the old press releases on the early findings and also some of the scientific papers. You'll also find they are testing derivative drugs that treat other diseases and injuries, like dementia, Parkinsons, and another one I think would be fantastic if it works out, spinal cord injuries.

Neotrofin is a unique drug they developed and they have a number of patents on it and similar drugs. They are a year or more ahead of any competitors in the field. That is at least a year, even if all the tests for any competitor yields the same test results.

Good luck with your research. If you learn anything new or get any insights that aren't already on the board, share them with the rest of us.